Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclopentolate
Drug ID BADD_D00547
Description A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.
Indications and Usage Used mainly to produce mydriasis and cycloplegia for diagnostic purposes.
Marketing Status approved
ATC Code S01FA04
DrugBank ID DB00979
KEGG ID D07759
MeSH ID D003519
PubChem ID 2905
TTD Drug ID D0B1EV
NDC Product Code Not Available
UNII I76F4SHP7J
Synonyms Cyclopentolate | Cyclogyl
Chemical Information
Molecular Formula C17H25NO3
CAS Registry Number 512-15-2
SMILES CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Punctate keratitis06.04.02.003---
Pyrexia08.05.02.0030.004897%
Rash23.03.13.0010.002448%-
Rash maculo-papular23.03.13.0040.001632%
Respiration abnormal22.02.01.0410.001632%-
Respiratory distress22.02.01.0120.001632%-
Restlessness17.02.05.021; 19.11.02.0020.001632%
Sedation17.02.04.0050.001632%-
Seizure17.12.03.0010.004897%
Somnolence17.02.04.006; 19.02.05.003--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.0120.004081%
Tachycardia02.03.02.0070.003265%-
Tremor17.01.06.0020.003265%
Unresponsive to stimuli17.02.05.0310.001632%-
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.0010.002448%
Vertigo04.04.01.003; 17.02.12.0020.002448%
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.0030.002448%
Sudden onset of sleep17.15.04.0030.001632%-
Necrotising colitis07.08.01.0130.002448%-
Vasodilation procedure25.03.01.001---
Eye movement disorder06.05.02.008; 17.02.05.0250.001632%-
Decreased appetite08.01.09.028; 14.03.01.005--
Psychotic disorder19.03.01.002--
Therapeutic product effect prolonged08.06.01.0540.005223%-
The 3th Page    First    Pre   3    Total 3 Pages